Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
CD8+ T-celclusters belangrijk voor immuuntherapie
dec 2025 | Dermato-oncologie, Immuuntherapie